Additionally, In HCC cells and xenograft tumors, betulin treatment inhibits cellular glucose metabolism to prevent metastatic potential and also facilitates the inhibitory effect of sorafenib on HCC through inhibition of SREBP-1 (163). The gene discussed is SREBF1; the disease is hepatocellular carcinoma.